Loading…
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-79M | $-70M | $-55M | -32.8% | - | 40.7% |
| 2024 | $0M | $-62M | $-50M | $-43M | -20.5% | - | -25.8% |
| 2023 | $0M | $-78M | $-67M | $-59M | -24.1% | - | 5.6% |
| 2022 | $0M | $-67M | $-63M | $-52M | -19.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 67.59 | 78.19 | 62.38 | 79.47 |
| Research And Development | - | 48.61 | 57.06 | 44.35 | 59.13 |
| Selling General And Administration | - | 18.98 | 21.13 | 18.03 | 20.34 |
| Total Expenses | - | 67.59 | 78.19 | 62.38 | 79.47 |
| Operating Income | - | -67.59 | -78.19 | -62.38 | -79.47 |
| Total Operating Income As Reported | - | -67.59 | -78.19 | -62.38 | -79.47 |
| EBITDA | - | -67.19 | -77.65 | -61.79 | -78.84 |
| Normalized EBITDA | - | -67.19 | -77.65 | -61.79 | -78.84 |
| EBIT | - | -67.59 | -78.19 | -62.38 | -79.47 |
| Interest Income | - | - | 11.33 | 12.80 | 9.68 |
| Net Interest Income | - | - | 11.33 | 12.80 | 9.68 |
| Other Non Operating Income Expenses | 0.30 | 4.28 | 11.33 | - | - |
| Other Income Expense | 0.30 | 4.28 | 11.33 | - | - |
| Interest Income Non Operating | - | - | 11.33 | 12.80 | 9.68 |
| Net Non Operating Interest Income Expense | - | - | 11.33 | 12.80 | 9.68 |
| Pretax Income | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income From Continuing And Discontinued Operation | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income From Continuing Operation Net Minority Interest | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income Common Stockholders | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income Including Noncontrolling Interests | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Normalized Income | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Diluted NI Availto Com Stockholders | - | -63.31 | -66.86 | -49.59 | -69.79 |
| Basic Average Shares | - | 55.71 | 55.98 | 56.59 | 57.33 |
| Diluted Average Shares | - | 55.71 | 55.98 | 56.59 | 57.33 |
| Reconciled Depreciation | - | 0.41 | 0.54 | 0.60 | 0.62 |
| General And Administrative Expense | - | 18.98 | 21.13 | 18.03 | 20.34 |
| Other Gand A | - | 18.98 | 21.13 | 18.03 | 20.34 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Design Therapeutics, Inc.this co. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| CorMedix Inc. | CRMD | $670M |
| - |
| - |
| - |
| - |
| 4.13 |
| 1.65 |
| 40.0% |
| 4.01 |
| Zevra Therapeutics, Inc. | ZVRA | $660M | 7.93 | 4.27 | 53.8% | 6.70 |
| SI-BONE, Inc. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| Peer Median | - | -6.62 | 3.99 | -36.8% | -0.07 | |